Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,249,421
  • Shares Outstanding, K 55,331
  • Annual Sales, $ 54,580 K
  • Annual Income, $ -555,630 K
  • 60-Month Beta 2.17
  • Price/Sales 77.30
  • Price/Cash Flow N/A
  • Price/Book 2.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -3.79
  • Number of Estimates 12
  • High Estimate -3.02
  • Low Estimate -4.11
  • Prior Year -2.72
  • Growth Rate Est. (year over year) -39.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.02 +6.64%
on 11/11/19
92.95 -17.37%
on 10/17/19
-11.34 (-12.87%)
since 10/11/19
3-Month
72.02 +6.64%
on 11/11/19
124.15 -38.14%
on 08/20/19
-42.02 (-35.36%)
since 08/13/19
52-Week
72.02 +6.64%
on 11/11/19
163.43 -53.01%
on 04/03/19
-43.48 (-36.15%)
since 11/13/18

Most Recent Stories

More News
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based...

BLUE : 76.80 (+0.72%)
FTSV : 10.19 (+5.60%)
SmarTrend Watching for Potential Rebound in Shares of Bluebird Bio Inc After 16.14% Loss

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $73.81 to a high of $77.97. Yesterday, the shares fell 16.1%, which took the trading range below the 3-day low of...

BLUE : 76.80 (+0.72%)
SmarTrend Watching for Potential Rebound in Shares of Bluebird Bio Inc After 10.78% Loss

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $77.29 to a high of $79.56. Yesterday, the shares fell 10.8%, which took the trading range below the 3-day low of...

BLUE : 76.80 (+0.72%)
bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

--Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin(TM) gene therapy for patients with sickle cell disease

BLUE : 76.80 (+0.72%)
Bluebird Bio Inc Falls 1.81% on Heavy Volume: Watch For Potential Rebound

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $80.05 to a high of $87.48. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of...

BLUE : 76.80 (+0.72%)
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of -5.67% and -15.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BLUE : 76.80 (+0.72%)
bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

--- ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process -

BLUE : 76.80 (+0.72%)
Bluebird Bio Inc Falls 8.79% on Heavy Volume: Watch For Potential Rebound

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $79.91 to a high of $81.18. Yesterday, the shares fell 8.8%, which took the trading range below the 3-day low of...

BLUE : 76.80 (+0.72%)
bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

bluebird bio, Inc. (Nasdaq: BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020.

BLUE : 76.80 (+0.72%)
Downtrend Call Working As Bluebird Bio Inc Stock Falls 26.4% (BLUE)

SmarTrend identified a Downtrend for Bluebird Bio Inc (NASDAQ:BLUE) on August 2nd, 2019 at $122.19. In approximately 3 months, Bluebird Bio Inc has returned 26.41% as of today's recent price of $89.92....

BLUE : 76.80 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLUE with:

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 80.34
1st Resistance Point 78.57
Last Price 76.80
1st Support Level 74.89
2nd Support Level 72.97

See More

52-Week High 163.43
Fibonacci 61.8% 128.51
Fibonacci 50% 117.72
Fibonacci 38.2% 106.94
Last Price 76.80
52-Week Low 72.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar